These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 10332707)
1. Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients. Rave K; Heinemann L; Puhl L; Gudat U; Woodworth JR; Weyer C; Heise T Diabetes Care; 1999 May; 22(5):865-6. PubMed ID: 10332707 [No Abstract] [Full Text] [Related]
2. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro. Ahmed AB; Mallias J; Home PD Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613 [TBL] [Abstract][Full Text] [Related]
3. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro. Ahmed AB; Home PD Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Albright ES; Desmond R; Bell DS Diabetes Care; 2004 Feb; 27(2):632-3. PubMed ID: 14747268 [No Abstract] [Full Text] [Related]
5. The use of lispro for high sugar content snacks between meals in intensive insulin regimens. Kong N; Kitchen MM; Ryder RE Diabet Med; 2000 Apr; 17(4):331-2. PubMed ID: 10821304 [No Abstract] [Full Text] [Related]
6. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Mohn A; Strang S; Wernicke-Panten K; Lang AM; Edge JA; Dunger DB Diabetes Care; 2000 Apr; 23(4):557-9. PubMed ID: 10857953 [No Abstract] [Full Text] [Related]
7. Basal insulin replacement and use of rapid-acting insulin analogues in patients with type 1 diabetes. Zinman B Endocr Pract; 2000; 6(1):88-92. PubMed ID: 11419927 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018 [TBL] [Abstract][Full Text] [Related]
9. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Rosenstock J; Park G; Zimmerman J; Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511 [TBL] [Abstract][Full Text] [Related]
10. Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation. Janssen MM; Casteleijn S; Devillé W; Popp-Snijders C; Roach P; Heine RJ Diabetes Care; 1997 Dec; 20(12):1870-3. PubMed ID: 9405909 [TBL] [Abstract][Full Text] [Related]